About Multiple Sclerosis (MS)

  1. Multiple Sclerosis is a demyelinating disease of the CNS in which the immune system attacks the myelin sheath in the brain and spinal cord.
  2. Scar tissue forms interfering with the brain’s ability to operate the body.
  3. There are no curative treatments available today.
MS, RRMS, MoveS-it Study

What is the MoveS-it Study?

Multiple Sclerosis (MS) Study of ANK-700 to Assess Safety and Immune Tolerance

We are investigating a potential treatment for Relapsing-Remitting MS (RRMS) in a phase 1 clinical study in volunteers with RRMS.

Are you qualified for the MoveS-it study?

  • 18 – 60 years old
  • RRMS diagnosis
  • Not wheelchair bound
  • Some medications allowed

If you answered yes to all of these questions use the link below to find out if you can participate.
Other criteria apply.

What is ANK-700?

ANK-700 is an investigational treatment for RRMS. It encompasses a previously identified myelin antigen that is implicated in driving Multiple Sclerosis. We deliver the antigen to the liver and immune system with our liver targeting glycosylation signature.

MS, RRMS, MoveS-it Study

About Clinical Research

What is clinical research?

Clinical research is the process of developing medicines or therapies to possibly prevent, treat, or help with diseases. Before a medicine can become widely available, it must be tested in a series of clinical trials (sometimes called clinical studies) to understand its safety and effectiveness.

Your safety is the top priority of any clinical trial

Our investigators closely monitor the health of everyone who volunteers for clinical trials and receives study medications. If your health gets significantly worse, your study team will decide the best way to protect your health. This might include leaving the study early.

The phases of clinical research

There are usually three phases of clinical trials that investigational medications must go through before regulatory authorities can consider approving them for wider use. These phases study different aspects about the investigational medications and look at it in different groups of people.

Phase 1

  • Is the investigational medication safe?

❯ A small group of patients or healthy volunteers

Phase 2

  • Is the investigational medication safe?
  • Is it effective?
  • How does it work in the body?

❯ A group of volunteers with the disease

Phase 3

  • Confirm the investigational medication is safe
  • Confirm it is effective
  • How does it work in the body?

❯ A larger group of volunteers with the disease

ANK-700 is in Phase 1

Taking part is voluntary

You do not need to take part in any clinical trial if you don’t want to. Even if you qualify and decide to join, you are free to leave at any time. Just let your study team know so they can do a final health check.

Taking part is at no cost to you

The study medication and all trial-related tests and procedures not considered part of your usual care are normally provided at no cost. If you live in the US, you don’t need insurance to participate. In some locations, transportation to and from study visits or reimbursement for travel-related costs may also be provided, so be sure to ask your study team.

For more information about living with Multiple Sclerosis, please visit:

Site Locations
For the MoveS-it Study

UC Health Neurosciences Center
Aurora, CO
PI: Amanda Piquet, MD
Study Contact: Jose Parra Gonzalez

Jefferson University Hospital
Philadelphia, PA
PI: Thomas Leist, MD
Study Contact: Angira Mathur

Advanced Neuroscience
Franklin, TN
PI: Samuel Hunter, MD
Study Contact: Front Office

Cleveland Clinic
Cleveland, OH
PI: Jeffrey Cohen, MD
Study Contact: Leah Tardivo

UT Health
Houston, TX
PI: J W Lindsey, MD
Study Contact: James Jemelka

U Kansas Medical Center
Kansas City, KS
PI: Sharon Lynch, MD
Study Contact: TBD

UT Southwestern Medical Center
Dallas, TX
PI: Benjamin Greenberg, MD
Study Contact: Taylor Quance

Multicare Health
Tacoma, WA
PI: Stacy Donlon, MD
Study Contact: Tonya Stigger

Barrow Neurological Institute
Phoenix, AZ
PI: Ram Narayan, MD
Study Contact: TBD

MS Center of Central Washington
Vienna, VA
PI: Heidi Crayton, MD
Study Contact: TBD


We are ensuring that our Phase 1 clinical sites are adhering to national, state, local, and clinical site guidelines during the ongoing COVID-19 pandemic.